PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.\', \'Sinovac Biotech, Beijing, China.\', \'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.\', \'National Institutes for Food and Drug Control, Beijing, China.\', \'Suining County Center for Disease Control and Prevention, Suining, Jiangsu Province, China.\', \'CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.\', \'Sinovac Life Sciences, Beijing, China. Electronic address: gaoq@sinovac.com.\', \'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1473-3099(20)30843-410.1016/S1473-3099(20)30843-4
?:hasPublicationType
?:journal
  • The Lancet. Infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 33217362
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33217362>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33217362>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all